Table 3.

Univariable associations between patient characteristics and BKPyV.

	N	n (%) with BKPyV	Hazard Ratio (95% Confidence Interval)	p-Value
Overall	102	18 (17.6)	--
Age, 5-year increase	--	--	1.04 (0.81–1.36)	0.77
Age
<65	54	11 (20.4)	1 (ref)	0.44
≥65	48	7 (14.6)	0.69 (0.26–1.76)
Race/ethnicity
African American	67	8 (11.9)	1 (ref)	0.03
White	27	6 (22.2)	2.05 (0.67–5.91)
Other	8	4 (50.0)	4.43 (1.18–14.1)
Cause of ESRD
Diabetes	46	10 (21.7)	1 (ref)	0.26
Hypertension	26	2 (7.7)	0.30 (0.05–1.16)
Other	30	6 (20.0)	0.91 (0.31–2.46)
Transplant type
DDKT	71	12 (16.9)	1 (ref)
DCD	28	6 (21.4)	1.21 (0.46–3.16)	0.88
LKT	3	0 (0.0)	--
History of hepatitis C
No	73	11 (15.1)	1 (ref)	0.32
Yes	29	7 (24.1)	1.62 (0.59–4.13)
History of hepatitis B
No	93	17 (18.3)	1 (ref)	0.82
Yes	9	1 (11.1)	0.83 (0.09–3.27)
Immunologic risk
No	92	13 (14.1)	1 (ref)	0.004
Yes	10	5 (50.0)	4.13 (1.32–11.0)
CMV risk
1	6	1 (16.7)	1 (ref)	0.96
2	48	9 (18.8)	0.99 (0.19–18.2)
3	48	8 (16.7)	0.86 (0.16–15.9)
cPRA > 0
0	94	14 (14.9)	1 (ref)	0.005
>0	8	4 (50.0)	4.34 (1.23–12.14)
Donor age, 5-year increase	--	--	0.94 (0.78–1.13)	0.53
Donor age
<40	45	9 (20.0)	1 (ref)	0.62
≥40	57	9 (15.8)	0.79 (0.31–2.03)
KDPI, 10-point increase	--	--	1.03 (0.85–1.26)	0.75
KDPI
<50	45	8 (17.8)	1 (ref)	0.94
≥50	54	10 (18.5)	1.04 (0.41–2.71)
Induction
<4 mg/kg	31	5 (16.1)	1 (ref)	0.97
>4 mg/kg	38	7 (18.4)	1.03 (0.33–3.50)
Basiliximab	33	6 (18.2)	1.14 (0.34–3.97)
Delayed graft function
No	71	11 (15.5)	1 (ref)	0.39
Yes	31	7 (22.6)	1.51 (0.56–3.84)